We found that 13 SFXN1 CpG sites (Figure 3a), of which 2 CpG sites (5′-UTR-S_Shelf-cg06573254 and TSS200-Island-cg17647431) were significantly related to the prognosis of BC patients (Table 2). This evidence concerns the gene SFXN1 and breast cancer.